Arcutis Posts Q2 Profit, Raises 2026 Sales Guidance to $525–$540M on ZORYVE Demand
ARQT sits 84% above its 52-week low of $13.695.
Summary
Arcutis delivered a strong Q2 with net income of $15.0M and product revenue of $129.9M, up 59% year-over-year, driven by ZORYVE demand. Management raised full-year 2026 sales guidance to $525–$540M, signaling confidence in the launch trajectory. Separately, Robert Lisicki was named interim chief commercial officer, effective August 21, replacing L. Todd Edwards. This follows recent FDA approvals for ZORYVE in pediatric psoriasis and an accepted supplemental NDA, reinforcing the commercial momentum.
At the time of this announcement, ARQT was trading at $25.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $13.70 to $31.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.